Literature DB >> 19006449

Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome.

Alok Upadhyay1, Nicholas M Ponzio, Virendra N Pandey.   

Abstract

Anti-human immunodeficiency virus-1 (HIV-1) polyamide (peptide) nucleic acids (PNAs) conjugated with cell-penetrating peptides (CPPs) targeted to the viral genome are potent virucidal and antiviral agents. Earlier, we have shown that the anti-HIV-1 PNA(TAR)-penetratin conjugate is rapidly taken up by cells and is nontoxic to mice when administered at repeat doses of as high as 100 mg/kg body weight. In the present studies we demonstrate that naked PNA(TAR) is immunologically inert as judged by the proliferation responses of splenocytes and lymph node cells from PNA(TAR)-immunized mice challenged with the immunizing antigen. In contrast, PNA(TAR)-penetratin conjugate is moderately immunogenic mainly due to its penetratin peptide component. Cytokine secretion profiles of the lymph node cells from the conjugate-immunized mice showed marginally elevated levels of proinflammatory cytokines, which are known to promote proliferation of T lymphocytes. Since the candidate compound, PNA(TAR)-penetratin conjugate displays potent virucidal and antiviral activities against HIV-1, the favorable immunological response together with negligible toxicity suggest a strong therapeutic potential for this class of compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006449      PMCID: PMC2948452          DOI: 10.1089/oli.2008.0152

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  43 in total

1.  A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA.

Authors:  L J Brandén; A J Mohamed; C I Smith
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

2.  Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids.

Authors:  Martin A Maier; Christine C Esau; Andrew M Siwkowski; Edward V Wancewicz; Klaus Albertshofer; Garth A Kinberger; Neena S Kadaba; Tanya Watanabe; Muthiah Manoharan; C Frank Bennett; Richard H Griffey; Eric E Swayze
Journal:  J Med Chem       Date:  2006-04-20       Impact factor: 7.446

3.  Comparison of novel delivery systems for antisense peptide nucleic acids.

Authors:  Laura Chiarantini; Aurora Cerasi; Alessandra Fraternale; Enrico Millo; Umberto Benatti; Katia Sparnacci; Michele Laus; Marco Ballestri; Luisa Tondelli
Journal:  J Control Release       Date:  2005-11-14       Impact factor: 9.776

4.  Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.

Authors:  Xin-Xing Tan; Jeffrey K Actor; Yin Chen
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.

Authors:  A Arnó; L Ruiz; M Juan; A Jou; M Balagué; M K Zayat; S Marfil; J Martínez-Picado; M A Martínez; J Romeu; R Pujol-Borrell; C Lane; B Clotet
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

6.  In vitro and in vivo nuclear factor-kappaB inhibitory effects of the cell-penetrating penetratin peptide.

Authors:  Tamás Letoha; Erzsébet Kusz; Gábor Pápai; Annamária Szabolcs; József Kaszaki; Ilona Varga; Tamás Takács; Botond Penke; Erno Duda
Journal:  Mol Pharmacol       Date:  2006-02-27       Impact factor: 4.436

7.  Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

Authors:  Y Levy; C Capitant; S Houhou; I Carriere; J P Viard; C Goujard; J A Gastaut; E Oksenhendler; L Boumsell; E Gomard; C Rabian; L Weiss; J G Guillet; J F Delfraissy; J P Aboulker; M Seligmann
Journal:  Lancet       Date:  1999-06-05       Impact factor: 79.321

8.  A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties.

Authors:  Binay Chaubey; Snehlata Tripathi; Sabyasachi Ganguly; Dylan Harris; Ralph A Casale; Virendra N Pandey
Journal:  Virology       Date:  2005-01-20       Impact factor: 3.616

9.  High-level IL-12 production by human dendritic cells requires two signals.

Authors:  A Snijders; P Kalinski; C M Hilkens; M L Kapsenberg
Journal:  Int Immunol       Date:  1998-11       Impact factor: 4.823

10.  Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.

Authors:  Snehlata Tripathi; Binay Chaubey; Sabyasachi Ganguly; Dylan Harris; Ralph A Casale; Virendra N Pandey
Journal:  Nucleic Acids Res       Date:  2005-08-02       Impact factor: 16.971

View more
  6 in total

1.  Design of embedded chimeric peptide nucleic acids that efficiently enter and accurately reactivate gene expression in vivo.

Authors:  Joy Chen; Kenneth R Peterson; Camelia Iancu-Rubin; James J Bieker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

2.  Nanoligomers Targeting Human miRNA for the Treatment of Severe COVID-19 Are Safe and Nontoxic in Mice.

Authors:  Colleen R McCollum; Colleen M Courtney; Nolan J O'Connor; Thomas R Aunins; Yuchen Ding; Tristan X Jordan; Keegan L Rogers; Stephen Brindley; Jared M Brown; Prashant Nagpal; Anushree Chatterjee
Journal:  ACS Biomater Sci Eng       Date:  2022-06-21

Review 3.  Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.

Authors:  Virendra N Pandey; Alok Upadhyay; Binay Chaubey
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

4.  Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors.

Authors:  Hadis Honarvar; Kristina Westerlund; Mohamed Altai; Mattias Sandström; Anna Orlova; Vladimir Tolmachev; Amelie Eriksson Karlström
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

5.  RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing.

Authors:  Alan Ann Lerk Ong; Jiazi Tan; Malini Bhadra; Clément Dezanet; Kiran M Patil; Mei Sian Chong; Ryszard Kierzek; Jean-Luc Decout; Xavier Roca; Gang Chen
Journal:  Molecules       Date:  2019-08-20       Impact factor: 4.411

Review 6.  Cell-Penetrating Peptides for Antiviral Drug Development.

Authors:  Melaine Delcroix; Lee W Riley
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.